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pressure to quit. CONCLUSIONS: Developing smoking cessation interventions 
based on punitive incentives or policies such as smoke free campuses may 
benefit KSA in the long run. MPOWER program may not be enough for improving 
smoking cessation in Saudi college students. Investing in programs that can 
mould the young minds at an early age to quit smoking need to be developed.  
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OBJECTIVES: To investigate the prevalence of cardiovascular risk factors among 
patients undergoing elective Coronary Artery Bypass Graft surgery (CABG) in 
Karachi, Pakistan. METHODS: Cardiothoracic surgery quality improvement is a 
core value of health care provision. In order to improve quality of care, 
information on key indicators needs to be systematically collected and 
maintained. In 2006, the cardiothoracic department at Aga Khan University 
developed an infrastructure that would enable us to answer the more 
challenging research queries in cardiac surgery practice. The resulting electronic 
cardiothoracic database is based on the Society of Thoracic Surgeons database. 
We chose the following aspects of patient care to be included in the database 
form: pre-surgery patient condition and medications, anesthesia information, 
perfusion information, surgery information, recovery information, status of the 
patient atdischarge, 30-days and 365-days post-surgery follow-up information 
.Information was collected through structured questionnaire and entered into 
Microsoft Access and analyzed in SPSS(Statistical package of social sciences). 
RESULTS: In this prospective study 2073 undergoing elective CABG were 
included. Mean age of the patients was 54.85±9.7 years, 14.7% of patients were 
females. Prevalence of risk factors among the study population, included: 47.10% 
were overweight, 14.7% were obese, 47.7% were diabetic, 69.50% were 
hypertensive, 50.20% were dyslipidemia, 47.7% were as smokers, 9.2% were in 
renal failure, addition, 53% of patients had family history of coronary artery 
disease, 46.7% had a history of myocardial Infarction (MI). The operative 
mortality rate was 0.3%. Post surgery complications included renal failure in 
14.8% of patients, arrhythmias in 7%, reoperation in 2.3%, prolonged ventilation 
in 3.1%. CONCLUSIONS: There is a high prevalence of risk factors like 
dyslipidemia, hypertension, diabetes and smoking for ischemic heart disease in 
our population. Once we establish this fact we will work to control the risk 
factors and reduce the burden of disease so that’s why this study is being done  
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OBJECTIVES: Post-transplant headache (post-TX HA) is a recognized 
complication in transplant procedures. Its treatment can be problematic given 
the status of the patient and other factors. But this complication is infrequently 
discussed as a significant clinical problem since this symptom is generally 
considered less important than other complications, like organ rejections. The 
objective of this study is to characterize post-TX HA and to assess the factors 
associated with post-TX HA. METHODS: A survey was developed to assess these 
poorly investigated factors and consisted of four sections, include patients’ risk 
factors for headaches, the characteristics of post-TX HA, patients’ headache 
management techniques and effectiveness, the demographics of the patients. 
The participants of the study were patients who received kidney transplants at 
University Hospital in Cincinnati, OH and who currently follow-up at the Kidney 
Transplant Clinic of University Hospital, where the survey was administered. 
Other data include current medications, alcohol/tobacco/illicit drug use, and lab 
values were collected as well. A logistic regression model was constructed to 
evaluate the factors associated with the post-TX HA with the consideration of 
common covariates. RESULTS: A total of 95 patients were included in this study. 
41 patients reported they had experienced at least one headache 
episodefollowing transplant. Compared to the counterpart, the headaches 
patients experienced post transplant were significantly associated with age 
(OR=0.947, 95% CI is 0.901 to 0.995) and presence of pre transplant headaches 
(OR=14.123, 95% CI is 3.810 to 52.346). In terms of comorbidities, only chronic 
pain (neck, back, shoulder, etc.) is a factor showing statistically significant 
association with post-TX HA (OR=7.269, 95% CI is 1.737 - 30.429). CONCLUSIONS: 
Patients who had headaches pre transplant and suffered chronic pain are more 
likely to have post-TX HA. In addition, compared to older patients, younger 
patients are more likely to experience headaches after transplant.  
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OBJECTIVES: The phosphate binders (PBs) sevelamer hydrochloride or carbonate 
(SH/SC) and lanthanum carbonate (LC) will be included in the Centers for 
Medicare and Medicaid Services (CMS) bundled payment scheme from 2016. The 
aim of this study was to determine the inflection point in daily drug dose at 
which a switch to LC becomes cost-effective in dialysis patients on SH/SC with a 
high pill burden. METHODS: A Microsoft Excel-based pharmacy budget impact 
model (BIM) was developed to carry out a comparative analysis of the cost 
impact of LC versus SH/SC therapy from the standpoint of a US-based dialysis 
organization. Model assumptions were based on published literature, market 
research data, and prescription information. User inputs included drug cost, 
adherence rate, number of patients on dialysis, first-line PB treatment, titration 
protocols, and serum phosphate target levels. RESULTS: The cost of an initial 
dose of SH/SC 4800 mg/day was lower than that of LC 1500 mg/day. After a first 
titration step, SH/SC 7200 mg/day vs LC 2250 mg/day was cost-neutral. Following 
a second titration step, SH/SC 9600 mg/day vs LC 3000 mg/day exhibited cost 
savings in favor of LC of $15/day vs SH and $8/day vs SC. The estimated potential 
cost saving of switching one patient to LC 3000 mg/day compared with up-
titration to SH or SC 9600 mg/day is $451 or $228/month, respectively. This 
equates to an estimated saving of $13.8 million/year for the 4096 patients who 
were modeled to switch to LC based on utilization data. CONCLUSIONS: BIM 
analyses indicate that the inflection point at which LC becomes cost-effective is 
SH/SC 7200 mg/day. Substantial savings in PB costs can be realized by switching 
patients to LC instead of increasing the SH/SC dose above 7200 mg/day. This 
strategy has the potential to reduce the overall budgetary impact for US-based 
dialysis centers under the CMS bundle.  
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OBJECTIVES: To compare the health care costs of acute urinary tract infections 
(UTIs) and genital infections (GIs) between adults with type 2 diabetes mellitus 
(T2DM) versus those without DM (no-DM). METHODS: Using administrative 
claims data and a retrospective cohort design, commercially-insured adults with 
UTIs (cystitis or urethritis) or GIs (vulvovaginal candidiasis, bacterial vaginosis, or 
balanitis) from 2006-2010 were selected. The first UTI or GI event after a 6-month 
continuous enrollment period was identified, with the event date as the index 
date. T2DM patients, identified by ICD-9 diagnosis codes and use of non-insulin, 
anti-diabetic medications, were matched with a 1:3 ratio to no-DM patients on 
gender, age group, index year, and recurrence status ( ≥2 events) in the 6-month 
pre-index period. Health care costs related to UTI and GI events in the 30-day 
post-index period were compared between T2DM and no-DM cohorts. RESULTS: 
Matched UTI cohorts included 314,390 males (mean age: 59) and 944,749 females 
(mean age: 57). Total health care costs (mean ± standard error) related to UTIs 
were higher for T2DM than no-DM among males ($569±13 vs. $412±5) and 
females ($437±5 vs. $303±2). Inpatient and outpatient costs related to UTIs were 
also higher for T2DM than no-DM among males ($265±11 vs. $148±4; $221±5 vs. 
$189±2) and females ($163±4 vs. $88±2; $190±2 vs. $152±1), respectively. Matched 
GI cohorts included 23,853 males (mean age: 53) and 336,932 females (mean age: 
50). Total health care costs related to GIs were higher for T2DM than no-DM 
among males ($457±30 vs. $332±14) and females ($181±6 vs. $133±1). The same 
pattern was observed for GI-related inpatient and outpatient costs. All cost 
differences between T2DM and no-DM were statistically significant (p<0.05 by 
Wilcoxon rank-sum test). CONCLUSIONS: Relative to non-diabetics with 
urogenital conditions, the costs of T2DM patients with urogenital conditions 
were significantly higher.  
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OBJECTIVES: Recent studies have demonstrated that birth-cohort (BC) versus 
risk-based (RB) screening for hepatitis C virus (HCV) infection in the U.S is cost-
effective. The cost and logistical implications of widespread screening and 
treatment are important considerations from a policy perspective; therefore, the 
aim of this study was to evaluate where the greatest potential for cost savings 
and quality adjusted life years (QALYs) gained exists, when comparing BC versus 
RB screening policies. METHODS: A published Markov model describing the 
natural history of HCV was adapted to a U.S setting. The BC target population 
was subjects born from 1945-65. Eligible patients identified were treated with a 
direct acting anti-viral (DAA) in combination with pegylated interferon plus 
ribavirin, achieving SVR rates of 0.78/0.76 for genotype 1 (Gt1) and 2/3 (Gt2-3) 
respectively for fibrosis stages F0-F2; 0.62/0.67 (Gt1/Gt2-3) for F3 and 0.62/0.57 
(Gt1/Gt2-3) in F4. Published U.S. 2011 costs were used and both costs and benefits 
were discounted at 3.0%. RESULTS: From a tested population of 66.2 million, 
1,070,840 were identified and 551,800 were allocated treatment over a ten year 
period. The cost-effectiveness (CE) of BC compared to RB screening and 
treatment was $32,945; with treatment prioritized towards F3/F4 the CE 
decreases to $23,269 and with treatment prioritized towards F0/F1 increases to 
$44,721. Furthermore, prioritizing treatment in more advanced patients had the 
potential to reduce costs by $3,169,477,535, increase QALYs by 159,098 and avoid 
an additional 31,636 HCV related complications compared to prioritizing 
treatment in less advanced patients. CONCLUSIONS: This study confirms that BC 
screening and treatment is cost-effective across all fibrosis stages and 
demonstrates that a strategy prioritizing treatment in F3/F4 would minimize the 
